Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine
Misato OgataHironaga SatakeTakatsugu OgataYukimasa HatachiShigeo HaraSeiichi HirotaHisateru Yasui
著者情報
ジャーナル オープンアクセス

2019 年 58 巻 22 号 p. 3243-3246

詳細
抄録

We herein report the first case in which an escalated dose of sunitinib was effective, even after dose reduction. A 64-year-old man with gastrointestinal stromal tumor of the small intestine discontinued adjuvant imatinib because of interstitial pneumonia. After two years, peritoneal recurrence was detected. Sunitinib was started at 50 mg/day for 4 weeks every 6 weeks, after which the dosage was reduced to 37.5 mg/day because of grade 1 gastritis, stomatitis, and a fever. Four months later, computed tomography showed progressive disease. As the adverse events were well-controlled by medication, we escalated the dose to 50 mg/day and achieved a partial response.

著者関連情報
© 2019 by The Japanese Society of Internal Medicine
前の記事 次の記事
feedback
Top